LXRβ-selective agonism represents a targeted strategy to simultaneously enhance APOE lipidation and reduce microglial cholesterol accumulation, addressing two interrelated pathogenic mechanisms in APOE4-associated neurodegeneration. The approach exploits the predominant CNS expression of LXRβ (NR1H2) to achieve therapeutic effects while potentially avoiding the hepatic lipogenic effects mediated by LXRα. Supporting this rationale, LXRβ-deficient mice develop age-dependent neurodegeneration with cholesterol accumulation, and APOE4 carriers demonstrate impaired LXR-driven ABCA1 transcription compared to APOE3, suggesting that enhanced LXRβ signaling could restore APOE lipidation in this vulnerable population. However, significant challenges temper this hypothesis: global LXR agonists have failed in clinical trials due to hepatomegaly and hypertriglyceridemia, LXRβ expression in liver contributes to lipogenesis with deletion causing hepatic triglyceride accumulation in aging, and activation-induced APOE expression in microglia could paradoxically increase APOE4 quantity and worsen pathological seeding.
...Curated pathway from expert analysis
flowchart TD
A["LXR-beta/NR1H2<br/>Nuclear Receptor"]
B["Oxysterol Ligand Binding<br/>24S-HC, 27-HC, GW3965"]
C["LXR/RXR Heterodimer<br/>DR4 Response Element"]
D["ABCA1/ABCG1<br/>Transcriptional Activation"]
E["APOE Lipidation<br/>Cholesterol Efflux"]
F["APOE4 Astrocytes<br/>LXR-beta Activity Reduced"]
G["Selective LXR-beta Agonist<br/>Avoids LIPID Toxicity"]
H["Cholesterol Homeostasis<br/>Neuroprotection"]
A --> B
B --> C
C --> D
D --> E
E --> H
F -.->|"impairs"| D
G --> C
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784
style H fill:#1b5e20,stroke:#81c784,color:#81c784No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for LXRΒ yet. Search RCSB →
Median TPM across 13 brain regions for LXRβ (NR1H2) from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for LXRβ (NR1H2).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF primary murine microglia are treated with 1 μM LXRβ-selective agonist (e.g., GSK2033) for 48 hours following loading with 50 μg/mL aggregated LDL to simulate cholesterol accumulation, THEN intracel | Microglial total cholesterol content decreases by ≥40% | — no observation — | pending | 0.58 |
| IF C57BL/6J mice receive daily subcutaneous injections of an LXRβ-selective agonist (e.g., 10 mg/kg GW3965 or equivalent) for 14 days, THEN brain tissue will show a ≥30% increase in APOE-associated ch | APOE lipidation status increases by ≥30% in brain parenchyma | — no observation — | pending | 0.65 |